One multi-omics study demonstrated that mTOR and PI3K-AKI axis were involved in gastric cancer immunity, and the related mutations were associated with better survival of patients with anti-PD-1/PD-L1 immunotherapy [33]. Here, CD274 is linked to gastric cancer.